Immunomet Therapeutics
Houston, US · Delaware corporation
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), an OxPhos inhibitor that targets the metabolic dependency of resistant cancer cells. Its lead candidate is in a Phase 1b/2a trial for advanced pancreatic cancer in combination with standard of care.
Founders & leadership
DW
Dean WelschExecutive
Reported raises · per SEC filings
Form D private placements$842.2K disclosed across 1 round · 2026
▶$842.2KraisedFeb 2026 · 4 investors · BiotechnologyRule 506(b)
▶$842.2KraisedFeb 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dean WelschExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $842.2K
- Proceeds to insiders
- $220K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Immunome20 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Immunomic Therapeutics18 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Immuneering16 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immune-Onc Therapeutics14 shared keywordsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Inimmune13 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Bioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Immunomet Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Immunomet Therapeutics do?
- ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), an OxPhos inhibitor that targets the metabolic dependency of resistant cancer cells. Its lead candidate is in a Phase 1b/2a trial for advanced pancreatic cancer in combination with standard of care.
- How much funding has Immunomet Therapeutics raised?
- Immunomet Therapeutics has disclosed $842.2K raised across 1 round.
- Where is Immunomet Therapeutics headquartered?
- Immunomet Therapeutics is headquartered in Houston, US.